PDS Biotech expands equity incentive plan

In a recent 8-K filing with the Securities and Exchange Commission, PDS Biotechnology Corporation (NASDAQ:PDSB), currently trading at $1.75 and valued by InvestingPro at Fair Value, announced the approval of an amendment to its 2014 Equity Incentive Plan. The clinical-stage immunotherapy company, with a market capitalization of $80 million, maintains a healthy balance sheet with more cash than debt, according to InvestingPro analysis. The amendment, which was subject to stockholder approval, was ratified during the company’s annual meeting on Wednesday. This approval results in an increase of 3,144,049 additional shares available for issuance, bringing the total to 9,709,584 shares. The company’s financial position shows a current ratio of 2.33, indicating strong liquidity to meet short-term obligations.

The annual meeting also saw the election of two Class A directors, Stephen Glover and Gregory Freitag, J.D., C.P.A., who will serve until the 2028 Annual Meeting of Stockholders. Additionally, stockholders ratified the appointment of KPMG US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of the company’s named executive officers in a non-binding advisory vote.

The detailed results of the votes for each proposal were disclosed, indicating the number of votes for, against, withheld, and broker non-votes. The amendment to the incentive plan saw 9,158,039 votes in favor, with 3,285,825 against and 846,475 abstaining. The election of directors, ratification of the accounting firm, and approval of executive compensation also passed with a majority of the votes.

The 8-K filing, which serves as the official record of these corporate actions, provides transparency and ensures that PDS Biotechnology’s stockholders are informed about the decisions affecting the governance and strategic direction of the company. These corporate governance measures reflect the company’s commitment to aligning the interests of its management and stockholders. Looking ahead, InvestingPro data reveals that two analysts have revised their earnings upwards for the upcoming period, with analyst price targets ranging from $4.50 to $13.00. Get deeper insights into PDSB’s financial health, growth prospects, and more with the comprehensive Pro Research Report, available exclusively on InvestingPro.

PDS Biotechnology is a Delaware corporation headquartered in Princeton, NJ, with a focus on pharmaceutical preparations. The information reported is based on the company’s SEC filing.

In other recent news, PDS Biotechnology Corporation reported a net loss of $8.5 million for the first quarter of 2025, an improvement from the $10.6 million loss in the same period last year. The company has been focusing on innovative therapies, which is reflected in decreased expenses and strategic collaborations. In clinical developments, PDS Biotech announced new data from its Phase 3 trial targeting HPV16-positive head and neck squamous cell carcinoma, revealing a median overall survival of 30.0 months. This result compares favorably to pembrolizumab monotherapy, which typically shows a median overall survival of 12-18 months. The trial, named VERSATILE-003, has reached complete enrollment with 53 patients across 31 sites in the US and Europe. H.C. Wainwright maintained a Buy rating on PDS Biotechnology, expressing encouragement with the clinical trial results. The firm noted that current standard-of-care therapies typically offer a median overall survival of approximately 18 months. PDS Biotech’s ongoing Phase 3 trial aims to further evaluate the efficacy of its combination treatment against pembrolizumab alone, with two interim analyses planned.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.